Pharmacological study and pharmaceutical intervention to reduce intravenous injection-induced vascular injury

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Takaaki Yamada

Abstract

Intravenous injection often causes vascular injury such as venous irritation, vascular pain, and phlebitis. Vascular injury deteriorates the patient's QOL and sometimes limits the continuation of injection therapy. Pharmaceutical intervention and pharmacological mechanisms used to reduce vascular injury induced by vinorelbine and epirubicin were reviewed. A multivariate logistic regression analysis revealed that the dose of vinorelbine (≥40 mg) was a significant predictor for venous irritation. Alteration of the volume of normal saline for vinorelbine dissolution, from 50 to 100 mL, significantly decreased the grade of venous irritation. On the other hand, the phlebitis scores were significantly higher in patients treated with epirubicin ready-to-use solution compared with lyophilized powder. The change of formulation of epirubicin to lyophilized powder decreased the risk of venous irritation. The concentration inducing 50% cell viability inhibition was lower in the order of vesicant, irritant, and nonvesicant drugs on porcine aorta endothelial cells (PAECs), suggesting that the injuring effects of anticancer drugs on PAECs may be relevant as an indicator of the frequency of their vascular injury. The exposure to vinorelbine of...Continue Reading

References

Mar 1, 1990·Blood Reviews·R T Dorr
Jan 18, 1989·Journal of the National Cancer Institute·L B GrochowR C Donehower
Mar 1, 1980·Cancer Treatment Reviews·R J Ignoffo, M A Friedman
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M SwainR A Gams
Apr 18, 2001·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·M VassilomanolakisA Efremidis
May 3, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S W LangerP B Jensen
Jun 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J PiccartJ M Nogaret
Dec 31, 2002·Journal of Molecular and Cellular Cardiology·Semon WuYing-Shiung Lee
Sep 27, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melina Verso, Giancarlo Agnelli
Apr 28, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y MinegishiY Nishiwaki
May 4, 2004·Japanese Journal of Clinical Oncology·Kiyotaka YohYutaka Nishiwaki
Nov 28, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kiyotaka YohYutaka Nishiwaki
Dec 1, 2006·The Journal of Pharmacology and Experimental Therapeutics·Emanuela SalvatorelliGiorgio Minotti
Dec 7, 2006·Oncology Nursing Forum·Carmel SauerlandDominick Corbi
Dec 23, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H T MouridsenG Giaccone
Jan 16, 2007·Vascular Pharmacology·Belay Tesfamariam, Albert F DeFelice
Jul 12, 2007·Clinical Journal of Oncology Nursing·Lisa Schulmeister
Mar 6, 2008·Journal of Pharmacological Sciences·Tomoko AkiRyozo Oishi
Apr 5, 2008·Journal of the American Academy of Nurse Practitioners·Esin Uslusoy, Samiye Mete
Aug 13, 2008·International Journal of Medical Sciences·Emiko KohnoKenji Matsuyama
Aug 15, 2009·International Journal of Medical Sciences·Emiko KohnoNoboru Okamura
Oct 20, 2009·Free Radical Biology & Medicine·Takaaki YamadaRyozo Oishi
Apr 27, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kenichiro NagataRyozo Oishi
Aug 2, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Takaaki YamadaRyozo Oishi
Sep 8, 2011·Journal of Pharmacological Sciences·Takaaki YamadaRyozo Oishi
Sep 20, 2011·Apoptosis : an International Journal on Programmed Cell Death·Lu ZhangLiangke Chen
Dec 24, 2011·Cell Biochemistry and Biophysics·Kun-Ling TsaiHsiu-Chung Ou
Feb 15, 2012·Free Radical Biology & Medicine·Takaaki YamadaRyozo Oishi
Dec 12, 2012·Physical Review Letters·M AblikimUNKNOWN BESIII Collaboration
Aug 28, 2013·Toxicology Mechanisms and Methods·Jie ZhangXiaoyan Zhao
Dec 19, 2013·Biochemical Pharmacology·Kun-Ling TsaiShing-Jong Lin
Jun 1, 2014·Cancer Chemotherapy and Pharmacology·Zhuo WangDingfeng Su

❮ Previous
Next ❯

Citations

Oct 6, 2018·Journal of Pharmaceutical Health Care and Sciences·Yoshihito MorimotoTakao Shinohara

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Kenichiro NagataRyozo Oishi
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Takaaki YamadaRyozo Oishi
© 2022 Meta ULC. All rights reserved